Images List Premium Download Classic

Prostate Cancer

Prostate Cancer-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods of treating prostate cancer with gnrh antagonist
Ferring B.v.
October 12, 2017 - N°20170290879

The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (gnrh) antagonist without causing a testosterone spike and/or other side effect of gnrh agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
Circulating tumor cell diagnostics for identification of resistance to androgen receptor targeted therapies
Epic Sciences, Inc.
October 05, 2017 - N°20170285035

The disclosure provides a method of predicting de novo resistance to androgen receptor (ar) targeted therapy in a tumor of a prostate cancer patient comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characteristization of nucleated cells in a blood sample obtained from the patient to generate circulating tumor cell (ctc) data, wherein the analysis comprises determining a ...
Compositions and methods for diagnosis and treatment of prostate cancer
Novartis Ag
October 05, 2017 - N°20170283807

The invention provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating subjects having tmprss2:erg positive prostate cancer, which we show is amenable to therapeutic treatment with a prmt5 inhibitor. Kits, methods of screening for candidate prmt5 inhibitors, and associated methods of treatment are also provided.
Prostate Cancer Patent Pack
Download 215+ patent application PDFs
Prostate Cancer Patent Applications
Download 215+ Prostate Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 215+ full patent PDF documents of Prostate Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compounds and methods for kinase modulation, and indications therefor
Obi Pharma, Inc.
October 05, 2017 - N°20170283423

In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more of fms, kit, flt3, trka, trkb and trkc kinase protein. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of one or more of fms, ...
Poly(adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
Institute For Cancer Research D/b/a The Research Institute Of Fox Chase Cancer Center
October 05, 2017 - N°20170283402

Compounds that are not related to nad, and which target parp1-histone h4 interaction are provided, as well as compositions of these compounds, and methods for specific inhibition of poly(adp-ribose) polymerase 1 (parp-1) using these compounds are provided. These parp-1 inhibitors may be used to treat cancer in which parp-1 activation or biologic activity plays a role, including prostate cancer, ...
Androgen receptor modulators and methods for their use
Institute For Cancer Research D/b/a The Research Institute Of Fox Chase Cancer Center
October 05, 2017 - N°20170283377

Or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein r1, r2, r3, r4, r6, y1 and y2 are as defined herein, and wherein at least one of r3 or r4 is a straight-chain c1-c6 haloalkyl, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds ...
Prostate Cancer Patent Pack
Download 215+ patent application PDFs
Prostate Cancer Patent Applications
Download 215+ Prostate Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 215+ full patent PDF documents of Prostate Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Psma-targeted nir dyes and their uses
On Target Laboratories, Llc
October 05, 2017 - N°20170281801

The present disclosure relates to prostate specific membrane antigen (psma) targeted compounds conjugated to near-infra red (nir) dyes and methods for their therapeutic and diagnostic use. More specifically, this disclosure provides compounds and methods for diagnosing and treating diseases associated with cells and/or vasculature expressing prostate specific membrane antigen (psma), such as prostate cancer and related diseases. The disclosure ...
Intravenous formulation and lc/ms/ms analysis method for gmc1
Texas Southern University
October 05, 2017 - N°20170281600

Certain embodiments are directed to a gmc1 co-solvent formulation. The gmc1 co-solvent formulation described herein can be used for the treatment of prostate cancer, benign prostatic hypertrophy, and other hormone-related conditions involving androgen, glucocorticoid, and progesterone receptors.
Methods of detecting prostate cancer
Texas Southern University
September 28, 2017 - N°20170275704

The invention described herein provides biological markers for the diagnosis, prognosis, and monitoring of prostate cancer
Methods and compositions related to prostate cancer therapeutics
The Johns Hopkins University
September 28, 2017 - N°20170275673

Disclosed herein are compositions and methods for detecting biological molecules and biomarkers associated with prostate cancer. Disclosed herein are compositions and methods for detecting biological molecules and biomarkers associated with castration-resistant prostate cancer wherein such biological molecules and biomarkers comprise androgen-receptor splice variants that can be used to develop effective therapeutic regimens for prostate cancer patients. Disclosed herein are methods ...
Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
The Board Of Regents Of The University Of Texas System
September 28, 2017 - N°20170275280

The present disclosure relates generally to derivatives of capsazepine and methods of use thereof in some aspects, the present disclosure relates to using capsazepine derivatives to treat cancer or other hyperproliferative diseases. In some aspects of the present disclosure, the disclosure provides capsazepine derivatives which may be useful in the treatment of cancer. Such cancers that the compounds may be ...
Histone demethylase inhibitors
Celgene Quanticel Research, Inc.
September 28, 2017 - N°20170275266

Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
The Johns Hopkins University
September 21, 2017 - N°20170268063

Methods of the present disclosure provide for detection of mutations and splice variants of the androgen receptor using a non-invasive approach, rnaseq, for examining circulating tumor cells.
Prostate Cancer Patent Pack
Download 215+ patent application PDFs
Prostate Cancer Patent Applications
Download 215+ Prostate Cancer-related PDFs
For professional research & prior art discovery
inventor
  • 215+ full patent PDF documents of Prostate Cancer-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Conjugates of ph low insertion peptide and monomethyl auristatins in the treatment of solid tumors
Lehigh University
September 21, 2017 - N°20170267727

Constructs comprising ph low insertion peptide and variants thereof conjugated to monomethyl auristatins and analogs thereof are described. These constructs are useful, for example, in the treatment of solid tumors, including the treatment of breast cancer and prostate cancer, as well as other cancers such as pancreatic cancer, ovarian cancer, cervical cancer, uterine cancer, lung cancer, skin cancer, kidney cancer, ...
Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
Vision Global Holdings Ltd.
September 21, 2017 - N°20170266285

The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i. E. Active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, ...
Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
University Of Maryland, Baltimore
September 21, 2017 - N°20170266181

Nonsteroid and steroid compounds that cause down-regulation of the androgen receptor (ar), both full length and splice variant, induce apoptosis and inhibit proliferation of inhibiting proliferation and migration of androgen sensitive cancer cells. The steroid compounds and nonsteroid compounds may be agents for the prevention and/or treatment of cancer, including prostate cancer, castration resistant prostate cancer, bladder cancer, pancreatic ...
Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia
Wavesense, Inc.
September 14, 2017 - N°20170261510

Disclosed are methods to induce dislodgement of target prostatic cells from the prostate organ, collecting said cells, and subsequently examining the cell population. Such methods comprise the administration of an agent that facilitates the dislodgement of the target cells from within the prostate, which then migrate into the urethra. Exemplary agents include 5 alpha-reductase inhibitors. The cells induced to pass into ...
Conjugates for treating diseases caused by psma expressing cells
Endocyte, Inc.
September 14, 2017 - N°20170258932

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by psma expressing cells, such as prostate cancer cells, using compounds capable of targeting psma expressing cells.
Fosfestrol for use in curative or palliative treatment of prostate cancer
Endocyte, Inc.
September 14, 2017 - N°20170258817

The invention further provides an oral dosage unit comprising at least 500 mg, of fosfestrol.
Method for treating prostate cancer
University Of South Carolina
September 14, 2017 - N°20170258793

The invention provides a method for treating prostate cancer in a subject comprising administering to the subject an effective amount of a selective inhibitor of one or more of cdk8 and cdk19. In some embodiments the inhibitor inhibits cdk19. In some embodiments, the inhibitor inhibits cdk8 at a kd of lower than 200 nm and/or inhibits cdk19 at a kd ...
Prostate cancer ablation
Lazure Scientific, Inc.
September 14, 2017 - N°20170258517

Methods and systems for delivering electrical energy and controlled, mild hyperthermia to a prostate tissue of a patient for destruction of cancerous and/or hyperplastic tissue. A method includes positioning a plurality of electrodes in a target tissue region comprising the prostate tissue, and establishing an alternating electrical current flow through a volume of the prostate tissue to induce mild ...
Loading